Talaris Therapeutics Earnings beat, Revenue Inline In Q3

Investing.com - Talaris Therapeutics reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Talaris Therapeutics announced earnings per share of $-0.46 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.49 on revenue of $0.00.
Talaris Therapeutics shares are down 4.96% from the beginning of the year and are trading at $1.51 , down-from-52-week-high.
Talaris Therapeutics shares gained 5.59% in intra-day trade the report.
Talaris Therapeutics follows other major Healthcare sector earnings this month
Talaris Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb
Drop an image here or